Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CODXNASDAQ:FEMYNASDAQ:NEPHNASDAQ:NMTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCODXCo-Diagnostics$0.30-1.3%$0.32$0.23▼$2.23$10.08M0.84240,860 shs222,163 shsFEMYFemasys$0.80$1.10$0.69▼$1.80$21.79M-2.62251,486 shs382,425 shsNEPHNephros$3.36-1.2%$2.23$1.36▼$3.66$35.62M0.9613,245 shs24,122 shsNMTCNeuroOne Medical Technologies$0.58-1.2%$0.59$0.40▼$1.39$28.98M0.65185,058 shs76,793 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCODXCo-Diagnostics-1.35%+14.54%-14.26%-46.41%-70.86%FEMYFemasys0.00%-9.10%-29.39%-46.67%-27.93%NEPHNephros-1.18%+27.76%+82.02%+103.64%+54.84%NMTCNeuroOne Medical Technologies-1.24%-5.32%-10.86%-40.97%-33.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCODXCo-Diagnostics3.8839 of 5 stars3.53.00.04.41.10.01.3FEMYFemasys3.6001 of 5 stars3.55.00.00.02.22.51.3NEPHNephros2.1136 of 5 stars3.55.00.00.00.90.80.0NMTCNeuroOne Medical Technologies2.0908 of 5 stars3.55.00.00.00.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCODXCo-Diagnostics 3.00Buy$5.501,732.72% UpsideFEMYFemasys 3.00Buy$8.67983.33% UpsideNEPHNephros 3.00Buy$5.0048.81% UpsideNMTCNeuroOne Medical Technologies 3.00Buy$1.45149.27% UpsideCurrent Analyst Ratings BreakdownLatest CODX, NMTC, NEPH, and FEMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025FEMYFemasysJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $6.005/9/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.005/5/2025NMTCNeuroOne Medical TechnologiesLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$1.454/28/2025CODXCo-DiagnosticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025CODXCo-DiagnosticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.003/28/2025CODXCo-DiagnosticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$1.50 ➝ $1.003/28/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/19/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $15.003/13/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCODXCo-Diagnostics$3.71M2.71N/AN/A$2.81 per share0.11FEMYFemasys$1.70M12.82N/AN/A$0.85 per share0.94NEPHNephros$15.52M2.30N/AN/A$0.80 per share4.20NMTCNeuroOne Medical Technologies$5.76M5.03N/AN/A$0.10 per share5.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCODXCo-Diagnostics-$35.33M-$1.17N/AN/AN/A-563.93%-54.94%-49.28%8/14/2025 (Estimated)FEMYFemasys-$14.25M-$0.91N/AN/AN/A-1,435.77%-141.49%-82.30%8/14/2025 (Estimated)NEPHNephros-$1.58M$0.07N/A∞N/A-6.86%-11.39%-8.30%8/7/2025 (Estimated)NMTCNeuroOne Medical Technologies-$12.32M-$0.22N/A∞N/A-82.17%-270.70%-129.70%8/13/2025 (Estimated)Latest CODX, NMTC, NEPH, and FEMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025NEPHNephros-$0.0050$0.0526+$0.0576$0.05$3.67 million$4.88 million5/13/2025Q2 2025NMTCNeuroOne Medical Technologies-$0.09-$0.07+$0.02-$0.07$1.27 billion$1.39 billion5/8/2025Q1 2025CODXCo-Diagnostics-$0.33-$0.24+$0.09-$0.24$0.38 million$0.05 million5/8/2025Q1 2025FEMYFemasys-$0.17-$0.23-$0.06-$0.23$1.14 million$0.34 million3/27/2025Q4 2024CODXCo-Diagnostics-$0.34-$0.36-$0.02-$0.36$0.38 million$0.15 million3/27/2025Q4 2024FEMYFemasys-$0.25-$0.23+$0.02-$0.23$1.66 million$0.58 million3/24/2025Q4 2024NEPHNephros-$0.01$0.03+$0.04$0.03$3.67 million$3.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCODXCo-DiagnosticsN/AN/AN/AN/AN/AFEMYFemasysN/AN/AN/AN/AN/ANEPHNephrosN/AN/AN/AN/AN/ANMTCNeuroOne Medical TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCODXCo-DiagnosticsN/A6.926.70FEMYFemasys0.863.943.26NEPHNephrosN/A6.954.02NMTCNeuroOne Medical TechnologiesN/A3.642.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCODXCo-Diagnostics14.99%FEMYFemasys65.27%NEPHNephros41.10%NMTCNeuroOne Medical Technologies16.07%Insider OwnershipCompanyInsider OwnershipCODXCo-Diagnostics8.40%FEMYFemasys11.54%NEPHNephros6.70%NMTCNeuroOne Medical Technologies8.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCODXCo-Diagnostics10033.57 million29.98 millionOptionableFEMYFemasys3027.24 million20.08 millionNot OptionableNEPHNephros3010.60 million10.11 millionNot OptionableNMTCNeuroOne Medical Technologies2049.82 million28.12 millionOptionableCODX, NMTC, NEPH, and FEMY HeadlinesRecent News About These CompaniesNeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate SecretaryJune 3, 2025 | globenewswire.comNeuroOne to Attend MedInvest’s MedTech, AI & Digital Health Conference on June 3-4, 2025May 29, 2025 | uk.finance.yahoo.comNeuroOne to Attend MedInvest's MedTech, AI & Digital Health Conference on June 3-4, 2025May 29, 2025 | globenewswire.comEarnings call transcript: NeuroOne Medical beats EPS expectations in Q1 2025May 15, 2025 | uk.investing.comNeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q2 2025 Earnings Call TranscriptMay 14, 2025 | msn.comNeuroOne Medical Technologies Corp (NMTC) Q2 2025 Earnings Call Highlights: Revenue Surge and ...May 14, 2025 | uk.finance.yahoo.comNeuroOne expects FY25 revenue to reach $8M–$10M as OneRF platform advances and new FDA submission broadens pipelineMay 13, 2025 | msn.comNeuroOne Medical Technologies Corporation (NMTC) Q2 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comNeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%May 13, 2025 | globenewswire.comNeuroOne Medical Technologies Corporation: NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical AdvisorMay 12, 2025 | finanznachrichten.deNeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical AdvisorMay 12, 2025 | globenewswire.comLadenburg Thalmann Initiates Coverage of NeuroOne Medical Technologies (NMTC) with Buy RecommendationMay 6, 2025 | msn.comNeuroOne Medical Announces Participation in The D. Boral Capital Inaugural Global ConferenceMay 5, 2025 | newsfilecorp.comNeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8:30 a.m. Eastern TimeMay 1, 2025 | globenewswire.comNeuroOne completes FDA submission for nerve ablation tech to treat facial painApril 24, 2025 | massdevice.comNeuroOne Medical completes FDA submission for OneRF Ablation System RFApril 24, 2025 | markets.businessinsider.comNeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial PainApril 23, 2025 | globenewswire.comNeuroOne Medical Technologies Corporation: NeuroOne Issues Letter to ShareholdersApril 17, 2025 | finanznachrichten.deNeuroOne says tariffs won’t impact business, Zimmer Biomet dealApril 17, 2025 | massdevice.comNeuroOne® Issues Letter to ShareholdersApril 16, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCODX, NMTC, NEPH, and FEMY Company DescriptionsCo-Diagnostics NASDAQ:CODX$0.30 0.00 (-1.35%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$0.30 0.00 (-0.70%) As of 06/6/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Femasys NASDAQ:FEMY$0.80 0.00 (0.00%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$0.83 +0.03 (+3.75%) As of 06/6/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.Nephros NASDAQ:NEPH$3.36 -0.04 (-1.18%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$3.36 +0.01 (+0.15%) As of 06/6/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.NeuroOne Medical Technologies NASDAQ:NMTC$0.58 -0.01 (-1.24%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$0.59 +0.01 (+1.43%) As of 06/6/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
